Applications of darbepoietin-α, a novel erythropoiesis-stimulating protein, in oncology

Current Opinion in Hematology

Volumn 9, Issue 3, 2002, Pages 228-233

  Smith, Robert ^a  

^a South Carolina Oncology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ANEMIA; ANIMAL MODEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FATIGUE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT;

CARCINOMA, SMALL CELL; DISEASE-FREE SURVIVAL; ERYTHROPOIESIS; ERYTHROPOIETIN; HUMANS; LUNG NEOPLASMS; NEOPLASMS;

EID: 0036209313     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200205000-00009     Document Type: Review

References (29)

1. New frontiers in oncology supportive care: Anemia management
2. Symptomatology of anemia
3. Anaemia and its functional consequences in cancer patients: Current challenges in management and prospects for improving therapy
4. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
5. Anaemia in cancer: Pathophysiology and treatment
6. Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition
7. Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors
8. Overview: Erythropoiesis, anemia, and the impact of erythropoietin
9. The impact of epoetin alfa on quality of life during cancer chemotherapy: A fresh look at an old problem
10. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
11. Oxygenation of human tumors: Implications for combined therapy
12. The negative impact of anemia on radiotherapy and chemoradiation outcomes
13. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review
14. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind placebo-controlled trial
15. Chemotherapy-induced anemia in adults: Incidence and treatment
16. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx
17. Novel erythropoiesis stimulating protein
18. Epoetin alfa practice pattern usage in community practice sites
19. Development and characterization of novel erythropoiesis stimulating protein (NESP)
20. Novel erythropoiesis stimulating protein (darbepoietin alfa) alleviates anemia associated with chronic inflammatory disease in a rodent model
21. The pharmacokinetics of ARANESP™ in oncology patients undergoing multicycle chemotherapy
22. Predictability of pharmacokinetic properties of NESP administered once every 3 weeks in patients with nonmyeloid malignancies receiving cyclic chemotherapy
23. Randomized, active-controlled, phase 1/2, dose-comparison study of NESP administered weekly or every 2 weeks in patients with solid tumors
24. A randomized, blinded, placebo-controlled, phase II, dose-finding study of NESP in patients with lymphoproliferative malignancies
25. A phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum-treatment for lung cancer
26. Erythropoietin for anaemia in cancer patients
27. Randomized, double-blind, placebo controlled, phase I/II dose finding study of ARANESP™ administered once every three weeks in solid tumor patients
28. Open-label, phase I/II dose escalation study of NESP in patients with chronic anemia of cancer
29. Improvement in haemoglobin levels improves health-related quality of life (HRQOL) of anaemic cancer patients